Omid Hamid, MD
Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.
Figure. Epacadostat Combination in Melanoma
CT indicates computed tomography; ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance imaging; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
The study is open to adult patients with unresectable stage III or stage IV melanoma not amenable to local treatment. Patients who have received prior systemic treatment for their disease, particularly therapy directed at the PD-1/PD-L1 pathway, CD137, or IDO1 are excluded from the trial. Anti-CTLA-4 therapy is permitted in the adjuvant setting.
... to read the full story